Novo Nordisk to cut some insulin prices by up to 75%
CBSN
Novo Nordisk plans to slash the U.S. list prices for several of its insulin drugs by as much as 75%, the company said on Tuesday. The move follows Eli Lilly's announcement earlier this month that it would cut prices on some of its insulin products.
Novo Nordisk, a Danish pharmaceutical firm, said it would reduce the cost of its NovoLog and NovoLog Mix 70/30 products by 75% and of Novolin and Levemir by 65%. The company will also lower list prices of unbranded pre-filled insulin pens, vials of long-acting and short-acting insulin, and pre-mixed insulin products to match the lowered price of each respective branded insulin product, the company said.
The cuts are slate to take effect on Jan. 1, 2024.

Washington — Amid Trump administration demands for Tehran to keep the free flow of commerce in the Strait of Hormuz, U.S. officials have told CBS News that there are at least a dozen underwater mines through the vital passageway, according to current American intelligence assessments. Arden Farhi, Kathryn Watson, Caroline Linton, Aimee Picchi and Layla Ferris contributed to this report.












